January 30, 2020 / 12:03 PM / 24 days ago

Biogen quarterly profit jumps on demand for multiple sclerosis drug

Jan 30 (Reuters) - Drugmaker Biogen Inc reported a 52.1% jump in fourth-quarter profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera, and strength in biosimilars business.

Net income attributable to the company rose to $1.44 billion, or $8.08 per share, in the quarter ended Dec. 31, from $946.8 million, or $4.73 per share, a year earlier. (bit.ly/38PYUP7)

Total revenue rose to $3.67 billion from $3.53 billion. (Reporting by Trisha Roy and Tamara Mathias in Bengaluru;Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below